Nutritional Prevention of Exertional Muscle Dysfunction (MUSREC)
Dietary Supplement: Choline
Dietary Supplement: Placebo
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Supportive Care
|Official Title:||Nutritional Prevention of Exertional Muscle Dysfunction|
- Creatine Kinase (CK) activity [ Time Frame: 3 weeks ]CK activity in response to an exertional challenge will be measured.
|Study Start Date:||November 2012|
|Estimated Study Completion Date:||November 2018|
|Estimated Primary Completion Date:||November 2018 (Final data collection date for primary outcome measure)|
Dietary Supplement: Choline
4 capsules with 480 mg choline per day
Placebo Comparator: Placebo
|Dietary Supplement: Placebo|
An initial screening questionnaire will determine general eligibility. The investigators will screen white young males with low to moderate choline intake (<450 mg/d) for CK response to exercise (high/low) by having them do intense eccentric exercise (12 elbow flexor contractions of non-dominant arm with dumbbell at 100% maximal lift capacity) and then 72 hours (3 days) later draw 250 μl capillary blood by finger stick for CK, metabolomic and genetic measurements.
The investigators plan to recruit 30 CK responders with an 1958 A allele of the methylenetetrahydrofolate dehydrogenase 1 (MTHFD1), which is present in about 60% of Caucasian males.
All participants will be asked to complete on three days 24-hour diet interviews with an online automated program provided by the National Cancer Institute. Participants of the intervention study will also have to be complete interviews on the final three days of the two intervention periods The recruited candidates will do an initial exercise challenge with no intervention, then a second challenge after three weeks with the first supplement (randomized choline or placebo), then a third challenge after another three weeks with the complementary second supplement (choline if they had placebo first, placebo if they had choline first).
Samples identified only by code will be stored indefinitely at the UNC Nutrition Research Institute to permit the analysis of additional genetic markers related to muscle health and choline metabolism when the capacity for the analysis of such markers becomes available. Such analyses may be carried out at the University of North Carolina Nutrition Research Institute (UNC NRI) or at external laboratories providing the service for the PI. Samples will be destroyed once no such additional analyses are intended or feasible anymore or if the investigators do not continue this research. Storage of the samples is not optional.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01722448
|Contact: Martin Kohlmeier, MD||(704) email@example.com|
|United States, North Carolina|
|UNC Nutrition Research Institute||Recruiting|
|Kannapolis, North Carolina, United States, 28081|
|Principal Investigator: Martin Kohlmeier, MD|
|Principal Investigator:||Martin Kohlmeier, MD||University of North Carolina|